SS
MPLT

SBI Securities’s MapLight Therapeutics MPLT Stock Holding History

SBI Securities’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.6K Buy
1,160
+603
+108% +$17.3K ﹤0.01% 1240
2026
Q1 		$11.3K Sell
557
-50
-8% -$894 ﹤0.01% 1674
2025
Q4 		$10.7K Buy
+607
New +$10.2K ﹤0.01% 1706

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SBI Securities's MPLT Position: Q2 2026 in Review

SBI Securities increased its MapLight Therapeutics (MPLT) stake by 108% in Q2 2026, buying an estimated $17.3K and bringing the position to 1,160 shares worth $41.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

SBI Securities first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • SBI Securities held 1,160 shares of MapLight Therapeutics worth $41.6K as of Q2 2026.
  • SBI Securities bought 603 MapLight Therapeutics shares in Q2 2026, an estimated $17.3K.
  • MapLight Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1240 holding.
  • SBI Securities first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.